London - The pharmaceuticals giant GlaxoSmithKline was yesterday given the go-ahead to market its HIV treatment Trizivir in EU member countries.
The medicine is the first of its kind to combine the anti-HIV therapies abacavir sulphate, lamivudine and zidovudine in one tablet.